Im vergangenen Jahr erzielte Trinity Biotech PLC für sein leistungsstärkstes Segment, Clinical Laboratory, Einnahmen von 31.68M USD. Die Region Americas leistete den größten Beitrag mit 32.39M USD im letzten Jahr.

Nach Geschäftsbereich

Umsatz

Anteil

Jährlich

Jährlich

Vierteljährlich

Clinical Laboratory

Point of care

Laboratory services

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

FY2018

FY2017

FY2016

FY2015

FY2014

FY2013

FY2012

FY2011

Clinical Laboratory

31.68M(72.35%)

39.37M(63.96%)

42.29M(74.41%)

46.04M(73.63%)

62.88M(77.49%)

84.28M(82.64%)

68.13M(75.33%)

71.62M(73.81%)

73.37M(74.00%)

74.17M(74.46%)

73.58M(73.43%)

84.84M(80.89%)

71.46M(78.34%)

63.36M(76.79%)

61.39M(78.75%)

Point of care

8.10M(18.50%)

17.43M(28.32%)

9.09M(16.00%)

9.21M(14.74%)

10.34M(12.74%)

9.21M(9.04%)

11.39M(12.60%)

14.84M(15.29%)

16.77M(16.92%)

16.91M(16.97%)

18.81M(18.77%)

20.04M(19.11%)

19.75M(21.66%)

19.15M(23.21%)

16.56M(21.25%)

Laboratory services

4.01M(9.15%)

4.75M(7.72%)

5.45M(9.59%)

7.27M(11.63%)

7.93M(9.77%)

8.48M(8.32%)

10.91M(12.07%)

10.58M(10.90%)

9.00M(9.08%)

8.54M(8.57%)

7.81M(7.79%)

--(--)

Nach Region

Umsatz

Anteil

Jährlich

Jährlich

Vierteljährlich

Americas

Ireland

Eliminations

Other Foreign

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

FY2018

FY2017

FY2016

FY2015

FY2014

FY2013

FY2012

FY2011

Americas

32.39M(73.98%)

41.79M(67.89%)

44.98M(79.15%)

50.51M(80.79%)

67.25M(82.87%)

77.69M(76.18%)

64.05M(70.82%)

65.86M(67.88%)

66.09M(66.67%)

63.89M(64.14%)

60.43M(60.31%)

61.61M(58.75%)

48.68M(53.37%)

42.03M(50.94%)

40.23M(51.61%)

Ireland

11.39M(26.02%)

19.76M(32.11%)

11.85M(20.85%)

12.01M(19.21%)

13.90M(17.13%)

24.29M(23.82%)

26.39M(29.18%)

31.17M(32.12%)

33.05M(33.33%)

35.72M(35.86%)

38.52M(38.45%)

40.98M(39.07%)

40.62M(44.53%)

40.48M(49.06%)

37.72M(48.39%)

Eliminations

--(--)

Other Foreign

--(--)

4.00K(--)

1.24M(1.24%)

2.29M(2.18%)

1.92M(2.11%)

--(--)